Hacktheripper.com

[illuminatii]

Wow good call Hack. Will remember this. Glad I held off till news hit.

[illuminatii]

Protecting profits. You're the man Hack!

[Hacktheripper]

DOW INDUSTRIALS -chart workup - Provided by Tim West

DOW INDUSTRIALS MONTHLY 100 YEARS CHART

[img]http://s3.amazonaws.com/tradingview/y/Yge4wWBH_big.png[/img


BUY STOCKS, INDIVIDUAL STOCKS, NOT THE MARKET. But I explain this at the end.

First, thanks to TradingView user russ.brown.52 for putting up your long term trendlines chart on the DJIA. I decided to add some internal trendlines (in green) that capture the movement within the extremes of price. You can see that those internal trendlines are just under the current market from 14000-9000, but rising steadily.

I then added some important points about how the FED has acted strongly to avoid the DISASTER that we experienced in the post 1974 environment for the stock market where inflation ripped apart the values of stocks by over 64%. Although most people argue that current inflation rates are much higher than are reported, keeping rates lower than historically normal has kept the system afloat and awash in cash and credit.

I then added the market cycles from 1942-1981 and 1981-present are very similar and fortunately for me I found the pattern in 2001 and have been able to find innumerable comparisons and unreal similarities of those two time frames. Although I missed publishing a book to announce to the world, I did present my findings to hundreds of people through my investment group, presentations direct to hedge funds and many individual investors over the past 13 years. I encourage you to read the books by Harry Dent. His books go a long way towards explaining the population cycles that drove this pattern. In short, we face the headwinds of people leaving the workforce in the next 10 years and the costs of caring for our elderly population. We also face the lack of spending from large family households going forward, which will restrain economic activity for well over a decade.

I hope you can take away from this chart that it is important to understand the long term cycles driving the market. I would add that it is important to begin to hedge any risks associated if the market were to return to its long term trends. The market is poised to drift sideways to up 30% for another 10-20 years and confound a majority of people. This chart shows us that we need to find other ways to grow our retirement portfolios because the average stock is not going to generate a big enough return. We have to find growth stocks that can increase by multiples as opposed to earning 3%-6% at best in the stock market for the next 10-20 years.

So, thank you to the FED for doing everything you could to keep from repeating the pattern of the past. And sorry to the savers and the retirees who have had to suffer because reported inflation is not keeping up with real-world price increases and for not being able to earn a decent return from your savings in the bank.

Thank you to those that fostered and encouraged the growth in the internet and all the technologies that support it. The internet is simply the greatest wealth building "FOUNTAIN OF WEALTH" since the internal combustion engine and electricity.

Tim West

[nightowwl]

Thank you so much!

[Hacktheripper]

AGEN 3.06 can it get past the 200 day



EHOS .005



SMAK .057 volume spike



PMCM - .0032 watch for volume



STEV .14 gap fills at .12



ONVO 5.58 - Tweezer Bottom



CBYI .0009

[Hacktheripper]

UTRM - .0044


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=100856701&txt2find=utrm

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=101023364&txt2find=utrm

[spdpro]

yep I saw that on the last build list 1860.9 on Sunday
glad that build went pretty smooth

[HeyEph]

Awesome! Thanks!

[illuminatii]

Ok ok ok you finally convinced me I am going to set up my account with them tonight. In order for you to get the free comissions is there somewhere I need to put your name down or do you need to send an email recommendation? Let me know.

[Hacktheripper]

ATTN: For all those of you using Ameritrade Thinkorswim Trading Platform:

My conversation with Ameritrade last week went well. I communicated the need to get trend line alerts. Today Im pleased to announce this is an new feature on Ameritrade's TOS platform as of April 26, 2014. For info on this feature click the link below.

http://tlc.thinkorswim.com/center/release/rel-04-26-2014.html?cid=SMTSMRTThinkorswimReleaseApril262014#AlertsonDrawings

For all the features added
click here

http://tlc.thinkorswim.com/center/release/rel-04-26-2014.html?cid=SMTSMRTThinkorswimReleaseApril262014

[TPX]

Hi Hacktheripper times throw a glance on it.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=101229737

[Hacktheripper]

PAL nice hammer on the daily chart with MACD 2 line about to cross support at .28, Keep an eye on Palladium prices that determines the direction more than anything

http://www.kitco.com/market/

[BlindSquirrelFindsNuts]

PAL - I have limited chart skills but it looks to me like the MACD is still turning up even with the new lows hit today? I'm always too early. Bought some .31s a couple weeks ago.

One day at a time

[TheInvincibleBull]

$MCII moving fast

[Hacktheripper]

GBR - possible dip and rip/Day Trade Only




CPHI .47 may run to 50 day MA



PAL .30 looks to have bottomed, Keep eye on Platinium Prices




HUSA - set volume alerts

[Hacktheripper]

Looks like Precious Metal Stocks are heating up, set your alerts


Percent Gainers More
Sym Name Last Chg Chg% Volume
1 GBR New Concept Energy, 2.40 0.56 30.63 2,573,661
2 CPHI China Pharma Holdings, In 0.47 0.06 14.55 346,438
3 DGSE Dgse Companies, Inc. 2.27 0.22 10.73 21,744
4 VHC Virnetx Holding Corp 16.02 1.37 9.35 1,693,694
5 BVX Bovie Medical Corp. 4.33 0.30 7.44 300,515
6 PLG Platinum Grp. Metals Ltd. 1.08 0.07 6.93 370,261
7 HUSA Houston American Energy C 0.50 0.03 6.38 258,233
8 THM International Tower Hill 0.68 0.04 6.25 112,925
9 TRX Tanzanian Royalty Explora 2.23 0.12 5.69 182,008
10 TRXC Transenterix, Inc. 4.35 0.23 5.58 1,092,508
11 ADGE American Dg Energy Inc. 2.47 0.13 5.56 144,421
12 AMCO Armco Metals Holdings, In 0.34 0.02 5.26 661,825
13 INUV Inuvo, New 0.83 0.04 5.06 637,056
14 SAND Sandstorm Gold Ltd. Ordin 5.53 0.26 4.93 425,606
15 FISK Empire State Realty Op, L 13.89 0.62 4.67 2,500
16 IDI Tiger Media, Inc. 0.92 0.04 4.55 54,040
17 ESBA Empire State Realty Op, L 13.90 0.60 4.51 20,560
18 AXX Alderon Iron Ore Corp. Or 1.61 0.07 4.45 9,691
19 TGD Timmins Gold Corp Common 1.42 0.06 4.41 217,912
20 LSG Lake Shore Gold Corp Ordi 0.79 0.03 4.32 387,326
21 GRF Eagle Capital Growth Fund 7.98 0.32 4.18 2,240
22 WGA Wells-gardner Electronics 1.81 0.07 4.02 200
23 BTG B2gold Corp Common Shares 2.96 0.11 3.86 1,577,219
24 EMAN Emagin Corp. 2.49 0.09 3.75 51,431
25 RVM Revett Mining Company, In 0.87 0.03 3.68 60,468
26 VGZ Vista Gold Corp 0.51 0.02 3.53 205,299
27 AAU Almaden Minerals, Ltd. Or 1.47 0.05 3.51 71,647
28 AXU Alexco Resource Corp Comm 1.31 0.04 3.15 283,442
29 IMH Impac Mortgage Holdings C 5.94 0.18 3.13 6,047
30 DXR Daxor Corp. 8.35 0.23 2.83 425
31 UUU Universal Security Instru 4.39 0.12 2.81 7,155
32 RBY Rubicon Minerals Corp. Or 1.12 0.03 2.75 844,044
33 UWN Nevada Gold & Casinos, In 1.17 0.03 2.63 20,470
34 NGD New Gold Inc. 5.11 0.13 2.61 1,811,401
35 MOC Command Security Corp. 2.00 0.05 2.56 3,630
36 NSU Nevsun Resources Ltd Ordi 3.61 0.08 2.27 589,404
37 NG Novagold Resources Inc. 3.66 0.08 2.23 1,030,861
38 QRM Quest Rare Minerals Ltd C 0.47 0.01 2.17 62,966
39 AUMN Golden Minerals Company 0.77 0.02 2.15 53,407
40 EGAS Gas Natural Inc. Common S 11.28 0.23 2.08 120,922
41 LIQT Liqtech International, In 2.00 0.04 2.04 30,253
42 CRVP Crystal Rock Holdings Cla 0.87 0.02 2.03 4,110
43 GPL Great Panther Silver Limi 1.02 0.02 2.00 342,516
44 HH Hooper Holmes, Inc. 0.62 0.01 1.97 179,945
45 CH Aberdeen Chile Fund (the) 10.91 0.21 1.96 23,706
46 AKG Asanko Gold Inc. 2.08 0.04 1.96 84,553
47 XXII 22nd Century Group, Inc. 2.20 0.04 1.85 200,715
48 GRH Greenhunter Resources, In 1.00 0.02 1.81 87,979
49 ONP Orient Paper New 2.39 0.04 1.70 10,492
50 MGN Mines Management, Inc. 1.23 0.02 1.64 61,811
51 RIC Richmont Mines, Inc. 1.30 0.02 1.55 54,025
52 BAA Banro Corporation Ordinar 0.48 0.01 1.48 828,690
53 EVY Eaton Vance New York Muni 14.22 0.20 1.44 14,245
54 NBW Neuberger Berman Californ 15.50 0.22 1.44 11,351
55 NYV Nuveen New York Municipal 14.44 0.20 1.40 7,678
56 ENSV Enservco Corp. 2.22 0.03 1.37 63,048
57 MVG Mag Silver Corp. Oridinar 7.32 0.09 1.24 15,529
58 LODE Comstock Mining, Inc. 1.70 0.02 1.19 54,105
59 MIW Eaton Vance Michigan Muni 12.76 0.15 1.19 121
60 MDW Midway Gold Corp. Ordinar 0.87 0.01 1.16 322,389
61 GTU Central Gold Trust Ordina 45.67 0.52 1.15 41,257
62 BONE Bacterin International Ho 0.70 0.01 1.14 283,936
63 MHE Blackrock Massachusetts T 12.82 0.14 1.11 4,414
64 ANV Allied Nevada Gold Corp. 3.70 0.04 1.09 3,548,909
65 EIP Eaton Vance Pennsylvania 12.82 0.13 1.02 3,051
66 NTS Nts, Inc. 1.98 0.02 1.02 15,453
67 CAW Cca Industries, Inc. 3.04 0.03 1.00 1,500
68 FRD Friedman Industries Inc. 8.43 0.08 0.96 5,753
69 CRV Coast Distribution System 3.21 0.03 0.94 315
70 GV Goldfield Corp. (the) 2.14 0.02 0.94 45,463
71 ETAK Elephant Talk Communicati 1.07 0.01 0.94 151,704
72 BLE Blackrock Municipal Incom 14.46 0.13 0.91 67,110
73 GGN Gamco Global Gold, Natura 10.20 0.09 0.89 431,644
74 CEF Central Fund Of Canada Li 13.97 0.12 0.87 564,248
75 FCO Aberdeen Global Income Fu 11.21 0.09 0.81 32,961
76 NGX Nuveen Massachusetts Amt- 12.67 0.10 0.80 1,978
77 NVX Nuveen California Dividen 14.00 0.11 0.79 29,061
78 VMM Delaware Investments Minn 13.96 0.11 0.78 30,788
79 NMZ Nuveen Municipal High Inc 12.99 0.10 0.78 102,234
80 BHV Blackrock Virginia Munici 15.80 0.12 0.77 2,541
81 OGCP Empire State Realty Op, L 13.50 0.10 0.75 3,954
82 REED Reeds, Inc. 5.46 0.04 0.74 10,428
83 ISL Aberdeen Israel Fund (the 18.20 0.13 0.72 7,521
84 UUUU Energy Fuels Inc. 8.45 0.06 0.72 38,728
85 NCB Nuveen California Municip 15.81 0.11 0.70 10,390
86 NPN Nuveen Pennsylvania Munic 14.45 0.10 0.70 6,389
87 NYH Eaton Vance New York Muni 11.99 0.08 0.67 1,719
88 UTG Reaves Utility Income Fun 28.72 0.19 0.67 73,401
89 AZC Augusta Resource Corp. Or 3.04 0.02 0.66 70,149
90 NVG Nuveen Dividend Advantage 13.75 0.09 0.66 22,570
91 RCG Renn Global Entrepreneurs 1.57 0.01 0.64 730
92 SBI Western Asset Intermediat 9.54 0.06 0.63 18,536
93 ERC Wells Fargo Advantage Mul 14.69 0.09 0.62 169,138
94 NOM Nuveen Missouri Premium I 14.57 0.09 0.62 1,752
95 NXK Nuveen New York Dividend 13.28 0.08 0.58 10,782
96 NZH Nuveen California Dividen 12.59 0.07 0.56 21,492
97 GSS Golden Star Resources, Lt 0.61 0.00 0.54 850,517
98 IFMI Institutional Financial M 1.92 0.01 0.52 1,967
99 BTI British American Tobacco 115.53 0.59 0.51 188,670
100 ADK Adcare Health Systems Com 4.03 0.02 0.50 36,211

[Hacktheripper]

I bookedmarked it will look when I have more time, thanks,

I will add to list later

[illuminatii]

Watching for continuation tomorrow.

[HeyEph]

Great list! Thanks, Hack! I've turned some people on to it, and suggested they follow you on twitter.

What do you think of this guys videos? Any good?
https://www.youtube.com/user/YourTradingCoach/featured

[illuminatii]

Levels and indicators to watch. Sorry I should post these all together.

[illuminatii]

[illuminatii]

Will be watching in the following weeks.

[Hacktheripper]

LUSI example of a frontloaded stock, I would expect the pump to start soon.

[TPX]

thx i have remark you!

[TPX]

hi hacktheripper, $MCET UPDATE! NEWS COMING!

$MCET MULTICELL TECHNOLOGIES FUTURE MULTI BILION $$$$$$ BIOTECH COMPANY$

MCT-125 PHASE IIb CLINICAL TRIAL

CLINICAL DEVELOPMENT & SUPPORT SERVICES LTD (CDSS) HAS
BEEN RETAINED BY MULTICELL TECHNOLOGIES TO MANAGE
MCT-125 PHASE IIb CLINICAL TRIAL

http://www.cdssltd.com/news-multicell.htm

14-Apr-2014 Quarterly Report

In December 2005, MultiCell exclusively licensed LAX-202 from Amarin Neuroscience Limited ("Amarin") for the treatment of fatigue in patients suffering from multiple sclerosis ("MS"). MultiCell renamed LAX-202 to MCT-125, and intends to further evaluate MCT-125 in a pivotal Phase IIb/III clinical trial. In a 138- patient, multi-center, double-blind placebo controlled Phase II clinical trial conducted in the United Kingdom by Amarin, LAX-202 demonstrated efficacy in significantly reducing the levels of fatigue in MS patients enrolled in the study. LAX-202 proved to be effective within four weeks of the first daily oral dosing, and showed efficacy in MS patients who were moderately as well as severely affected. LAX-202 demonstrated efficacy in all MS patient sub-populations including relapsing-remitting, secondary progressive and primary progressive. Patients enrolled in the Phase II trial conducted by Amarin also reported few if any side effects following daily oral dosing of LAX-202. MultiCell intends to proceed with the anticipated Phase IIb/III trial of MCT-125 using the data generated by Amarin for LAX-202 following discussions with the regulatory authorities.

http://biz.yahoo.com/e/140414/mcet10-q.html

Partner: AMARIN

http://www.multicelltech.com/about-us/partners/

Multicell intends to proceed with the anticipated pivotal Phase IIb/III trial of MCT-125 using the data generated by Amarin for LAX-202 following discussions with the FDA. If MCT-125 is approved for the treatment of fatigue in MS patients by the FDA and other such regulatory agencies, and is successfully commercialized, Multicell estimates MCT-125 could generate up to $3 billion in cumulative worldwide sales during the time MCT-125 is under patent protection. If such revenue forecasts are realized by MCT-125, under the terms of the agreement, Amarin could receive up to $275 million in milestone payments and cumulative royalty payments during the same period.

http://65.17.196.124/pdf/RDDIrections.pdf

Dr. Stephen Chang, President of Multicell said, “We are excited about in-licensing MCT-125 from Amarin to complement our emerging MS therapeutics program. MCT-125 targets the fatigue symptom while MCT-175, our internally developed humanized antibody therapeutic, is for treatment of the underlying cause of MS. As we undertake additional clinical studies, we are optimistic MCT-125 will continue to demonstrate efficacy for the treatment of fatigue in MS patients.”

http://www.sec.gov/Archives/edgar/data/897448/000095016206000002/ex99_1.htm

$$$ THE STENT OF THE FUTURE $$$

IDEAL BIOSTENT XENOGENICS POST CLINAL TRIALS 1st

Bioresorbable Scaffolds

Stent
Ideal Biostent

Strut Composition
PLA anhydride

Drug elution
Sirolimus

Company
Xenogenics

Development ---> Pre-clinical ---> Clinical trials 1st ---> Post Clinal Trials 1st

sbhci.org.br/2013/wp-content/uploads/2013/08/26/cacau/YaronAlmagor.pdf

$$$ New Directions for Stent Technology $$$

http://www.dicardiology.com/article/new-directions-stent-technology

$$$ Polymer vs. Metal: The Battle of Bioresorbable Stents $$$

http://www.mddionline.com/article/polymer-vs-metal-battle-bioresorbable-stents

$$$ Progress in Treatment by Percutaneous Coronary Intervention:
The Stent of the Future $$$

http://pdf.revespcardiol.org/watermark/ctl_servlet?_f=10&pident_articulo=90202865&pident_usuario=0&pcontactid=&pident_revista=255&ty=23&accion=L&origen=cardio&web=www.revespcardiol.org&lan=en&fichero=255v66n06a90202865pdf001.pdf

$$$ Fa2N-4 cell lines Patents $$$

Partner: CORNING

http://www.multicelltech.com/about-us/partners/

MultiCell has an exclusive license and purchase agreement with Corning of Corning, New York. Under the terms of such agreement, Corning has the right to develop, use, manufacture and sell MultiCell's Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (ADME/Tox assays). Corning paid MultiCell a non-refundable license fee, purchased certain inventory and equipment related to MultiCell's Fa2N-4 cell line business, hired certain MultiCell scientific personnel, and paid for access to MultiCell's laboratories during the transfer of the Fa2N-4 cell lines to Corning. MultiCell retained and continues to support all of its existing licensees. MultiCell retained the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. MultiCell also retained rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol? liver assist device, to identify drug targets and for other applications related to the Company's internal drug development programs.

http://biz.yahoo.com/e/140414/mcet10-q.html

Note 6 – Deferred Revenue

Corning Incorporated

The Company has an exclusive license and purchase agreement (the “Agreement”) with Corning of Corning, New York. Under the terms of the Agreement, Corning has the right to develop, use, manufacture, and sell the Company’s Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (“ADME/Tox assays”). The Company retained and will continue to support all of its existing licensees. The Company retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. The Company also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to produce therapeutic proteins using the Company’s BioFactories™ technology, to identify drug targets and for other applications related to the Company’s internal drug development programs. In consideration for the license granted, Corning paid the Company $375,000 upon execution of the Agreement, and an additional $375,000 upon the completion of a transition period. In addition, Corning purchased inventory and equipment from the Company and reimbursed the Company for laboratory costs and other expenses during a transition period. The Company is recognizing the income ratably over a 17 year period. The Company recognized $44,118 in income for each of the fiscal years ended November 30, 2013 and 2012. The balance of deferred revenue from this license is $477,942 and $522,059 at November 30, 2013 and 2012, respectively, and will be amortized into revenue through October 2024.

http://www.sec.gov/Archives/edgar/data/811779/000114420414012288/v367480_10k.htm

US PATENTS

US7566567 Immortalized Hepatocyte #PLACING#

http://www.google.com./patents/US7566567

US20070104696A1 Use of cell lines to produce active therapeutic proteins #REGISTRATION#

http://www.google.com./patents/US20070104696A1

US20070004039A1 Immortalized hepatocytes #REGISTRATION#

http://www.google.com./patents/US20070004039A1

EP EUROPEAN PATENTS

EP1704227B1 IMMORTALIZED HEPATOCYTES #PLACING#

http://www.google.com./patents/EP1704227B1

EP1685252A2 Use of cell lines to produce active therapeutic proteins #REGISTRATION#

http://www.google.com./patents/EP1685252A2

MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
MultiCell Strengthens Its Liver Cancer Drug Target Identification and Cancer Stem Cell Research Program

WOONSOCKET, R.I., Aug. 20 /PRNewswire-FirstCall/

WOONSOCKET, R.I., Aug. 20 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.
The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies. MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.

http://www.prnewswire.com/news-releases/multicell-technologies-is-granted-us-patent-for-immortalized-human-liver-cell-lines-62268362.html

$$$ MCT-485 Preclinical Development $$$

Drug Watch
Liver Cancer Drug Watch (Therapies in Development)
Updated March 1, 2014

Gene Silencing Switch off genes coding for tumor growth proteins.

MCT-485

Kills tumor cells and stimulates immune system

MultiCell Technologies, Woonsocket, RI

Preclinical

http://livercancerconnect.org/drug-watch

MultiCell Technologies MCT-485 MCET MultiCell Technologies' MCT-485 is a very small noncoding double stranded RNA (dsRNA).

double stranded RNA (dsRNA) = (siRNA + mRNA)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=100096762

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=100102222

MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer

MultiCell Technologies, Inc.
March 20, 2014 8:39 AM

WOONSOCKET, R.I., March 20, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has filed additional U.S. and international patent applications covering MCT-485 and its composition of matter, biological targets, mechanism of action, and methods and formulations for therapeutic use.

http://finance.yahoo.com/news/multicell-technologies-files-u-international-123900101.html

$$$ TOP PATENTS $$$

Any proprietary protection that we can obtain and maintain will be important to our business.

On September 7, 2005, MCTI, entered into an Asset Contribution Agreement (the “Asset Contribution Agreement”) with MultiCell, Alliance Pharmaceutical Corp. (“Alliance”), and Astral, Inc. (“Astral,” and together with Alliance, (“Transferors”). Pursuant to the Asset Contribution Agreement, MCTI issued 490,000 shares of common stock to Alliance in consideration for the acquisition of certain assets and the assumption of certain liabilities relating to Transferors’ business. The intellectual property acquired by MCTI includes ten United States and 20 foreign issued and pending patents and patent applications related to chimeric antibody technology, treatment of Type 1 diabetes, T-cell tolerance, TLR technology, dendritic cells, dsRNA technology and immunosuppression.

In December 2003, we acquired the exclusive worldwide rights to US Patent # 6,129,911, for Liver Stem Cells from Rhode Island Hospital. We agreed to pay an annual license fee of $20,000 for the first three years of the applicable license agreement and $10,000 per annum thereafter until a product is developed. Once a product is developed, if ever, the annual license fee will end and we will pay Rhode Island Hospital a five percent royalty on net sales of any product we sell covered by the patent until we pay an aggregate of $550,000 in royalties and a two percent royalty thereafter until the expiration of the patent. The expiration date of this patent is October 10, 2017.

In April 2005, we were granted US Patent # 6,872,389 for the liver stem cell invention of Dr. Ron Faris, MultiCell’s former Senior Vice President and Chief Scientific Officer. This patent contains 24 claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to our adult stem cell portfolio. The expiration date of this patent is July 8, 2019.

We have an exclusive, long-term license agreement with Rhode Island Hospital for use of the following patents owned by the hospital related to liver cell lines and Liver Assist Devices (LADs):

US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015;
US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019;
US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017; and
US Patent #6,872,389 Liver Stem Cell expires on July 8, 2019.

If we generate revenues and pay royalties, the annual license fee structure does not apply. Our agreement with Rhode Island Hospital provides that we would pay a five percent royalty until we pay Rhode Island Hospital an aggregate of $550,000. After that, the royalty percentage decreases to two percent for the life of the patents.

On November 3, 2003, Xenogenics was notified by the United States Patent and Trademark Office that its patent application for an “Artificial Liver Apparatus And Method”, the Sybiol® Synthetic Bio-Liver Device, would be allowed. United States patent 6,858,146 was issued in 2005. The expiration date of this patent is February 22, 2026. The Sybiol® trademark is registered in the United States Patent and Trademark Office, number 2,048,080.

Xenogenic’s Ideal BioStent™ is covered by patents owned by Rutgers and exclusively licensed to Xenogenics. The license between Xenogenics and Rutgers includes exclusive license rights and option to 23 issued patents and 61 patent applications with claims encompassing the basic design and synthesis of certain bioabsorbable polymers and their use in combination with drugs in medical devices.

The patent estate acquired by Xenogenics as part of its acquisition of the Ideal BioStent™ includes one issued U.S. patent and four patent applications. This patent estate covers the composition and synthesis of the Ideal BioStent™ proprietary bioabsorbable polymers, admixing of drugs and bioabsorbable polymers for therapeutic applications, and the use of these bioabsorbable polymers in stents and other medical devices.

http://www.sec.gov/Archives/edgar/data/811779/000114420414012288/v367480_10k.htm

US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015

Isolation and culture of porcine hepatocytes US 6017760 A

ABSTRACT

A perfusion device such as a liver assist device containing a housing defining a perfusion inlet and a perfusion outlet, a porous membrane structure mounted within said housing to define a perfusion compartment and an adjacent hepatocyte compartment, and porcine hepatocytes isolated from a porcine liver by retrograde perfusion.

http://www.google.com/patents/US6017760

US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019

Immortalized hepatocytes US 6107043 A

ABSTRACT

The invention features a virally-immortalized mammalian hepatocyte, which is derived from a normal liver cell, has differentiated hepatocyte-specific metabolic activity, has the ability to proliferate, and is nontumorigenic after prolonged culture.

http://www.google.com/patents/US6107043

US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017

Liver stem cell US 6129911 A

ABSTRACT

The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.

http://www.google.com/patents/US6129911

US Patent #6,872,389 Liver Stem Cell expires on July 8, 2019

Liver stem cell US 6872389 B1

ABSTRACT

The invention provides methods of isolating a primary liver stem cell by identifying a cell doublet containing a hepatocytes and the stem cell and isolating the doublet from liver tissue.

http://www.google.com/patents/US6872389

US Patent #6,858,146 Artificial Liver Apparatus And Method

Artificial liver apparatus and method US 6858146 B1

ABSTRACT

Artificial liver devices and methods for using the devices to purify a biological fluid are disclosed. The methods include the use of living hepatocytes (23) which are either unattached or attached to inert carriers and suspended in a cell culture medium which circulates in the devices with the hepatocytes (23). Blood or plasma passes on one side (7?) of semi-permeable membranes, on the other side (7) of which is the cell culture medium and across which is a concentration and/or pressure gradient. Solutes diffusing across the membrane into the cell culture medium are metabolized by the hepatocytes (23) and/or captured by additional removal means (4). Those undesirable substances which do not diffuse out of the blood or plasma into the hepatocyte containing culture medium are captured by additional removal means (50).

http://www.google.com/patents/US6858146

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc.

http://www.multicelltech.com/therapeutic-pipeline/published-patents/

MCET Multicell Technologies Partners

AMARIN / CORNING / PFIZER

http://www.multicelltech.com/about-us/partners/

$DAILY$



$WEEKLY$

[glenn1919]

PMRS..LATF..PMCM..UTRM..ADCS..DOMK..MLHC..BABL..TALK..FRZT..http://stockcharts.com/h-sc/ui?s=PMRS&p=D&b=5&g=0&id=p46096761453

http://stockcharts.com/h-sc/ui?s=LATF&p=D&b=5&g=0&id=p46096761453
http://stockcharts.com/h-sc/ui?s=PMCM&p=D&b=5&g=0&id=p46096761453
http://stockcharts.com/h-sc/ui?s=UTRM&p=D&b=5&g=0&id=p46096761453
http://stockcharts.com/h-sc/ui?s=ADCS&p=D&b=5&g=0&id=p46096761453
http://stockcharts.com/h-sc/ui?s=DOMK&p=D&b=5&g=0&id=p46096761453
http://stockcharts.com/h-sc/ui?s=MLHC&p=D&b=5&g=0&id=p46096761453
http://stockcharts.com/h-sc/ui?s=BABL&p=D&b=5&g=0&id=p46096761453
http://stockcharts.com/h-sc/ui?s=TALK&p=D&b=5&g=0&id=p46096761453
http://stockcharts.com/h-sc/ui?s=FRZT&p=D&b=5&g=0&id=p46096761453

....http://www.otcmarkets.com/stock/MLHC/news

....http://www.otcmarkets.com/stock/TALK/news

....http://www.otcmarkets.com/stock/BABL/news

[illuminatii]

Got the new scans up check them out all. Happy trading.
http://investorshub.advfn.com/Illuminati-28233/

[illuminatii]

Need to get you in that top 50! Any insight into my sat. scans? Sections I should add, drop, etc.?

[Hacktheripper]

I got the pump on,,,, but not planning the dump part

[illuminatii]

Hack you almost broke the 700 member marks! Congrats man. Seems like a couple weeks ago you broke 600

[Hacktheripper]

Moving up on smaller volume leads to selling on news..... FWIW

[illuminatii]

My take on MINE chart. Would the falling volume trump all these other indicators?

[Hacktheripper]

No problem, Best of luck on your trip

[BigT65]

Planning to watch these early next week as I will be travelling to Tampa. It will pass the time in the hotel, I hate travelling, been there done that all my life.

Thanks a lot Hack for all the time you spend keeping us informed.

[Hacktheripper]

If you find more good videos, shoot me a link and I will add them

[redsolocup]

Thanks Hack. Really appreciate the time you put in on this. A keeper!

[KAdams65]

Thanks. Do you have a rule about buying at the open?

[Hacktheripper]

Nice setup, watched it yesterday, looking for big buys

[andaros]

Excellent work Hack
Keep it up

[KAdams65]

Hack opinions on RSH this morning?

[Hacktheripper]

TRADING & CHARTING INSTRUCTION VIDEOS



BASICS

Stock Basics: 3 Different Types of Stock

Understanding the Different Between Swing Trading and Day Trading

Order Types (market, limit, stop, stop-limit)

Understanding Japanese Candlesticks

Stock Chart Reading Basics #1 - What kind of chart to use?

TNA 1 = Technical Analysis Tutorial Candlesticks

Basic Stock Chart Reading Lessons #1

Basic Stock Chart Reading Lesson #2

Stock Chart Reading Basics #3 - Support and Resistance

How to Read Stock Charts

How to Read Candlestick Charts

How To Trade Candlesticks

Trading strategy- Learn about the basics of candlestick charting

The Basics of Trend Trading

TECHNICAL ANALYSIS & STRATEGIES & PATTERNS

Trading strategy - Technical indicators explained

Chart Patterns Simple Indicators

Understanding Stock Trading Technical Analysis Tutorial

Pull Back Swing Trading Strategy

Stock Market Chart Patterns: Channels - Technical Analysis

Analyzing Technical Chart Patterns

Trading the Cup and Handle - Stock Chart Pattern

BOLLINGER BANDS


Short Term Trading Indicators - Using Bollinger Bands

Trading with Bollinger Bands

How The Pro's Trade Bollinger Bands Technical Analysis

MACD

How to Trade the MACD Indicator Like a Pro Part 1

MACD Indicator: Trade it Like a Pro (Part 2)

Trading the MACD Moving Average Convergence Divergence

How The Pro's Trade Using MACD Technical Analysis

MACD Settings

STOCHASTICS

Trading with the Stochastic Oscillator Part 1 of 2

Trading with the Stochastic Oscillator Part 2 of 2

How to Trade Stochastics Like the Pro's Do

How The Pro's Trade Using Stochastic Technical Analysis

RSI

Trading with RSI

How The Pro's Trade Using Relative Strength Index (RSI)

How to Trade the Relative Strength Index (RSI) Like a Pro

OBV

Trading with On Balance Volume (OBV)

PARABOLIC SAR

Parabolic SAR Buy & Sell Signals

TRENDLINES

Understanding Trend Lines

Technical Analysis: Trend Lines within Stocks

Stock Chart Reading Basics #2 - Trend Lines

ACCUM/DIST LINE

Trading with the Accumulation Distribution Line

MOVING AVERAGES

Trading with the Moving Averages

How The Pro's Trade Using Moving Average (MA)

CCI

CCI Indicator Variations

ELLIOTT WAVES

Elliott Waves and Cycles of time

FIBONACCI

Fibonacci Retracement Part 1 - Intro

Fibonacci Retracement Part 2 - Tops & Bottoms

How The Pro's Trade Using Fibonacci Retracements/Extension TA

SUPPORT AND RESISTANCE

Day Trading Lesson 5: Support and Resistance

The Importance of Support and Resistance

OTHER

Understanding Gaps: Common, Breakaway, Runaway, and Exhaustion Gap

Stock Market Charts: Double Top - Technical Analysis

Trading the Triple Top Stock Chart Pattern - Technical Analysis

Stock Trading Chart Patterns: Double Bottom

How to Trade the Wedge Chart Pattern Like a Pro Part 1

How to Trade the Wedge Chart Pattern Like a Pro Part 2

How to Trade Spinning Tops and Doji Candlestick Patterns

How to Trade the Head and Shoulders Pattern Part 1

How to Trade the Head and Shoulders Pattern Part 2

Continuation chart patterns

How to Use Level 2 While Trading Stocks

How to Recognize Penny Stock Dilution

"Selling the gap" -- How to sell the gap for profits on stocks

Don't chase! Why you must exercise patience

Multi Time Frame Analysis

How Successful Traders Use Indicators to Place Stops

Using Stops & Trailing Stops In Trading

Technical Indicators - The 3 Different Types

Using Technical Analysis The Right Way To Make Money

Trading strategy - Learn about 5 common trading mistakes to avoid

Trading strategy - How does creating a trading plan help build your strategy

Trading strategy - Stop loss strategies explained

[Hacktheripper]

Maybe I should have played

Hacktheripper ?@Hacktheripper1 6h
$LPPI I dont like these low float plays, and won't play myself, it is breaking out of downward trendline now and could run nicely. .0024 now
Collapse Reply Delete Favorite More
6:16 AM - 24 Apr 2014 · Details

[crafjs01]

LVGI starting to look good on the daily

[Hacktheripper]

UTRM

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=101035705

Hacktheripper Member Level Thursday, 04/24/14 07:59:03 AM
Re: bbq man post# 51671
Post # of 51676
Im not impressed with the pumping that occurred on Sunday to Monday, 4000+ posts in about 24 hours. Frankly, it was leading the sheep to the slaughter and the chart reflects that.

Here was my original post on this board, notice it was premarket, and I as an experienced trader knew what was going to happen.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=100856701&txt2find=pump

[Hacktheripper]

Ayrot Cannabis Index

http://ayrot.com/?page_id=16

[AxiomCloud]

Check my posts Ive never pumped, and I'm not even in the position. Might jump back in today depending on how it goes.

It has potential, but its not there yet. Hopefully the CEO follows through and has big thing in the works.

[Hacktheripper]

Now thats what I'm looking for, IMHO add the vortex indicator for a lower study, gives you insight when to enter so your not sitting on dead money waiting for it to run.

[Hacktheripper]

Why are you pumping the POS then...

over 4,000+ posts in 24hours, unreal, someone has to bring facts to the table when you pump that hard.

[BigT65]

Said same in IC chat last night. This confirms my thought process is at least on the right track. Although I did not correlate the move to a prior move as you did. Awesome chart Hack! Will be watching also.

[AxiomCloud]

Why are you trolling on the UTRM board then sparky?

That has the be the fruitiest image I've seen on ihub so far. Congrats.